癌症及其微环境中精准医学的迫切需求：以多发性骨髓瘤为例
The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma.
作者信息
Solimando Antonio Giovanni, Krebs Markus, Bittrich Max, Einsele Hermann
机构信息
Guido Baccelli Unit of Internal Medicine, Department of Biomedical Sciences and Human Oncology, School of Medicine, Aldo Moro University of Bari, 70124 Bari, Italy.
Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
出版信息
J Clin Med. 2022 Sep 16;11(18):5461. doi: 10.3390/jcm11185461.
Abstract
Precision medicine is particularly relevant for cancer and microenvironment deconvolution for therapeutic purposes in hematological and non-hematological malignancies [...].
摘要
精准医学对于癌症以及在血液系统和非血液系统恶性肿瘤中出于治疗目的进行微环境反卷积分析尤为重要[...]。
相似文献
1
The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma.
J Clin Med. 2022 Sep 16;11(18):5461. doi: 10.3390/jcm11185461.
2
[Precision medicine in hematological malignancies].
Rinsho Ketsueki. 2019;60(9):1386-1395. doi: 10.11406/rinketsu.60.1386.
3
Cancer associated fibroblasts in hematological malignancies.
Oncotarget. 2015 Feb 20;6(5):2589-603. doi: 10.18632/oncotarget.2661.
4
[EZH2 is therapeutic target for personalized treatment in multiple myeloma].
Bull Cancer. 2018 Sep;105(9):804-819. doi: 10.1016/j.bulcan.2018.06.003. Epub 2018 Jul 2.
5
The role of the tumor microenvironment in hematological malignancies and implication for therapy.
Front Biosci. 2005 May 1;10:1581-96. doi: 10.2741/1642.
6
Targeting immune checkpoints in hematological malignancies.
J Hematol Oncol. 2020 Aug 12;13(1):111. doi: 10.1186/s13045-020-00947-6.
7
Inhibition of Cytosolic Phospholipase A2α Induces Apoptosis in Multiple Myeloma Cells.
Molecules. 2021 Dec 9;26(24):7447. doi: 10.3390/molecules26247447.
8
The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.
Front Immunol. 2022 Jul 25;13:925266. doi: 10.3389/fimmu.2022.925266. eCollection 2022.
9
Myeloid-derived suppressor cells in hematological malignancies: friends or foes.
J Hematol Oncol. 2019 Oct 22;12(1):105. doi: 10.1186/s13045-019-0797-3.
10
The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease.
PLoS One. 2016 May 9;11(5):e0155087. doi: 10.1371/journal.pone.0155087. eCollection 2016.
引用本文的文献
1
Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity.
J Transl Med. 2024 Feb 27;22(1):208. doi: 10.1186/s12967-024-05013-0.
2
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting.
Biomedicines. 2023 Jul 24;11(7):2087. doi: 10.3390/biomedicines11072087.
本文引用的文献
1
A Proliferation-Inducing Ligand and B-Cell Activating Factor Are Upregulated in Patients with Essential Thrombocythemia.
J Clin Med. 2022 Aug 9;11(16):4663. doi: 10.3390/jcm11164663.
2
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
Nat Commun. 2022 Aug 3;13(1):4517. doi: 10.1038/s41467-022-32145-y.
3
The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring "Multiple Myelomas".
Cancers (Basel). 2022 Jul 4;14(13):3271. doi: 10.3390/cancers14133271.
4
The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value.
J Clin Med. 2022 Apr 29;11(9):2513. doi: 10.3390/jcm11092513.
5
Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
Nat Rev Clin Oncol. 2022 Apr;19(4):223-236. doi: 10.1038/s41571-021-00593-y. Epub 2022 Jan 11.
6
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.
Biomark Res. 2022 Jan 9;10(1):1. doi: 10.1186/s40364-021-00344-2.
7
Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications.
Sci Adv. 2021 Nov 19;7(47):eabg9551. doi: 10.1126/sciadv.abg9551. Epub 2021 Nov 17.
8
Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy.
Cancer Biol Ther. 2021 Jun 3;22(5-6):404-412. doi: 10.1080/15384047.2021.1946458. Epub 2021 Jul 21.
9
Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma.
NPJ Precis Oncol. 2021 Jun 28;5(1):60. doi: 10.1038/s41698-021-00185-0.
10
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
Nat Commun. 2021 Mar 25;12(1):1861. doi: 10.1038/s41467-021-22140-0.
Zotero 插件